NCT03344211 2026-02-27
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
Phase 2 Active not recruiting
Clinical Trials
18 trialsNCT02749903 2026-02-11
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT03246347 2026-01-23
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT02452008 2025-12-19
Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT05189457 2025-12-04
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT02312557 2025-12-03
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04335682 2025-11-04
ARACOG
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT04557449 2025-10-01
CDK4i
Pfizer
Phase 2 Active not recruiting
NCT03860987 2025-09-08
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04015622 2025-08-20
PROTRACT
British Columbia Cancer Agency
Phase 2 Active not recruiting
NCT01990196 2025-08-17
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04471974 2025-07-22
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Active not recruiting
NCT02955394 2025-07-09
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT02750358 2025-06-22
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04262154 2025-04-27
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03700099 2024-04-15
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting